PEPCLUB.me

Mitochondrial HealthAnti-AgingMetabolic HealthCardiovascular HealthArticlePremium

Humanin

10mg Vial

2 September 2026Updated 2 September 2026

Humanin

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Humanin.

Create free account Member login

Full range of benefits for Humanin

Neuroprotective activity in preclinical models of neurodegeneration

Anti-apoptotic effects protecting cells from stress-induced death

Enhances mitochondrial function and cellular bioenergetics

May improve insulin sensitivity and glucose regulation in animals

Reduces oxidative stress and intracellular reactive oxygen species

Modulates inflammatory signaling to lower pro-inflammatory cytokines

Cardioprotective effects in preclinical ischemia-reperfusion models

Influences autophagy and proteostasis under cellular stress

Associated with improved cellular survival during metabolic stress

Linked to lifespan and age-related resilience in some model systems

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 17 known interactions

Synergistic(4)Compatible(5)Monitor(4)Avoid(4)

Use with professional oversight

Insulin and sulfonylureas

Because Humanin can enhance insulin sensitivity, monitor blood glucose and adjust insulin or sulfonylurea doses to reduce hypoglycaemia risk.

Cytotoxic chemotherapy

Humanin's anti-apoptotic effects could alter tumour response to cytotoxic agents, so monitor treatment response and tumour markers closely.

Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)

Potential mitochondrial and immune-modulating overlap warrants monitoring drug levels, renal function, and immune status when combined with Humanin.

Glycaemic control biomarkers (fasting glucose, HbA1c)

Monitor standard glycaemic biomarkers during co-administration to detect altered insulin sensitivity and guide therapeutic adjustments.

All interaction categories

Synergistic (4)

Metformin: Metformin and Humanin both improve insulin sensitivity and mitochondrial function, potentially producing additive metabolic and cytoprotective effects.
GLP-1 receptor agonists (e.g., liraglutide): GLP-1 agonists provide complementary metabolic and neuroprotective actions that may enhance Humanin's insulin-sensitizing and neuroprotective benefits.
Nicotinamide riboside / NAD+ precursors: NAD+ precursors support mitochondrial bioenergetics and may augment Humanin's mitochondrial protective and anti-apoptotic activity.
Coenzyme Q10 (ubiquinone): As a mitochondrial antioxidant, coenzyme Q10 can complement Humanin's mitochondrial stabilization and reduce oxidative stress synergistically.

Compatible (5)

ACE inhibitors (e.g., lisinopril): No known direct pharmacodynamic or pharmacokinetic interaction with Humanin; compatible when managing cardiovascular comorbidities.
ARBs (e.g., losartan): Angiotensin receptor blockers have no established interaction with Humanin and are generally safe to co-administer.
Thiazide diuretics (e.g., hydrochlorothiazide): Thiazide diuretics do not have known interactions with Humanin and can be used without special dosing adjustments.
Low‑dose aspirin: Low‑dose aspirin for antiplatelet therapy has no reported interaction with Humanin and is considered compatible.
Vitamin D supplementation: Vitamin D has no known adverse interaction with Humanin and may be co-administered safely when indicated.

Monitor (4)

Insulin and sulfonylureas: Because Humanin can enhance insulin sensitivity, monitor blood glucose and adjust insulin or sulfonylurea doses to reduce hypoglycaemia risk.
Cytotoxic chemotherapy: Humanin's anti-apoptotic effects could alter tumour response to cytotoxic agents, so monitor treatment response and tumour markers closely.
Calcineurin inhibitors (e.g., tacrolimus, cyclosporine): Potential mitochondrial and immune-modulating overlap warrants monitoring drug levels, renal function, and immune status when combined with Humanin.
Glycaemic control biomarkers (fasting glucose, HbA1c): Monitor standard glycaemic biomarkers during co-administration to detect altered insulin sensitivity and guide therapeutic adjustments.

Avoid (4)

Active malignancy or cancer-directed therapies: Due to Humanin's cytoprotective and anti-apoptotic properties, use with caution in patients with active cancer as it may protect tumour cells from therapy.
Pregnancy and breastfeeding: Safety data for Humanin in pregnancy and lactation are limited, so avoid use unless potential benefits clearly outweigh risks and monitor closely.
Drugs that promote cellular proliferation (e.g., growth hormone, IGF-1 therapies): Combining Humanin with pro-proliferative agents may potentiate cell-survival and growth signals and should be evaluated for proliferative risk.
Known mitochondrial toxins (e.g., zidovudine/high-dose mitochondrial-toxic antivirals): Co-administration with agents that impair mitochondrial function warrants careful risk–benefit assessment because of potential unpredictable mitochondrial interactions.